For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ORGANIZATION
ORGANIZATION
- Industry Calls for Definition of “Basic Drugs”: FPMAJ Committee
June 15, 2015
- EFPIA Japan Chief Frets Negative Market Growth amid Pressure on Drug Costs
June 11, 2015
- Industry, Govt, Academia Should Discuss Challenges Facing Biosimilars: Prof. Kurokawa
June 9, 2015
- PhRMA Chairman Says Budget Issues Controllable with Generics
June 4, 2015
- JPMA to Draft Format of Application for Approval for Biopharmaceuticals
June 4, 2015
- US, European Lobbies Set Out Healthcare Policy Proposals for Japan
June 1, 2015
- JPWA Chief Suzuki Renews His Resolve as He Wins Second Term
June 1, 2015
- JPMA Extends Suspension of Activities for Takeda as It Awaits Ruling of Administrative Authority on Blopress Scandal
May 29, 2015
- Doctors Need to Be More Cost-Conscious When Prescribing: Dr Imamura of JMA
May 29, 2015
- FPMAJ, JPMA, and JGA Call for “Balanced” Approach to Control Drug Expenditure in Joint Declaration
May 28, 2015
- Generic Makers Need More Time to Meet Higher Target: JGA Leader
May 27, 2015
- 3 Companies Received Guidance, 2 Received Warnings in FY2014 due to Fair Competition Code Violations: Maker’s FTC
May 27, 2015
- JPMA Chief Fires at Proposed 80-90% Generic Share Target
May 27, 2015
- JPMA Official Praises Sakigake System as “Ground-Breaking,” Expresses Concern Over Impact of Compassionate Use System
May 12, 2015
- “Stable Supply System” Key for Adopting Generics at Insurance Pharmacies: JGA Survey
May 11, 2015
- JPMA Preparing “Action Guidelines” to Ensure Greater Transparency
April 24, 2015
- Expert Warns against Research-Driven Makers’ Foray into Indian Market
April 22, 2015
- JPMA to Step Up Calls for Biowaivers Using IVIVC
April 21, 2015
- MHLW to Inquire with Drug Makers about Payments to PAFSC Members
April 17, 2015
- Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…